A COMPARISON BETWEEN TREATMENT RESPONSE OF CHRONIC MYELOID LEUKEMIA PATIENTS RECEVING IMATINIB OR NILOTINIB

This study aimed to evaluate early hematologic responses after three months of TKI therapy in CML patients and to assess the influence of demographic and clinical factors on treatment outcomes.